Lisata Therapeutics
LSTA
27 hedge funds and large institutions have $10.1M invested in Lisata Therapeutics in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.68% less ownership
Funds ownership: 11.22% → 10.54% (-0.68%)
5% less call options, than puts
Call options by funds: $2.08M | Put options by funds: $2.18M
16% less funds holding
Funds holding: 32 → 27 (-5)
22% less capital invested
Capital invested by funds: $12.9M → $10.1M (-$2.79M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$328K |
| 2 |
Renaissance Technologies
New York
|
+$162K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$85.9K |
| 4 |
Goldman Sachs
New York
|
+$85.1K |
| 5 |
Millennium Management
New York
|
+$32.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$766K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$172K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$134K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$119K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$68.3K |
LSTA Hedge Fund Activity: Q2 2021 in Review
27 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2021, worth a combined $10.1M — down 22% from $12.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LSTA and 3 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was State Street, opening a new position worth an estimated $328K. The largest seller was Sabby Management, exiting entirely with an estimated $766K sold.
- 27 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2021, down from 32 in Q1 2021.
- Funds reported $10.1M of Lisata Therapeutics stock for Q2 2021, down 22% quarter-over-quarter.
- 3 funds opened new Lisata Therapeutics positions in Q2 2021 and 8 closed out, a net change of -5 holders.
- The largest Lisata Therapeutics buyer in Q2 2021 was State Street, an estimated $328K added.
- The largest Lisata Therapeutics seller in Q2 2021 was Sabby Management, an estimated $766K sold.
Based on aggregated 13F filings for Q2 2021.